Previous 10 | Next 10 |
2024-01-24 20:45:03 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed Q2 2024 Earnings Preview ResMed product recall classified as most serious by FDA (update) Read the full article on Seeking Al...
2024-01-24 16:10:05 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards ResMed Q2 2024 Earnings Preview ResMed product recall classified as most serious...
Year-over-year revenue grows 12% , operating profit down 2% , non-GAAP operating profit up 20% Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m....
FFW Corp. (FFWC) is expected to report for Q2 2024 ResMed Inc. (RMD) is expected to report $1.81 for Q2 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2023-12-31 ChoiceOne Financial Services Inc. (COFS) is expected to report $0.64 for Q4 2023 First ...
2024-01-23 17:35:36 ET Major earnings expected after the bell on Wednesday include: Tesla ( TSLA ) International Business Machines Corporation ( IBM ) ServiceNow ( NOW ) Lam Research Corporation ( LRCX ) Crown Castle ( CCI ) Read the full ar...
2024-01-23 17:35:15 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards ResMed product recall classified as most serious by FDA (update) ResMed masks to...
2024-01-22 00:41:37 ET Summary I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will have little effect on the Company. ...
2024-01-18 15:04:14 ET More on ResMed ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards A First Look At ResMed ResMed masks to remain on market despite recall: report ResMed alerts customers to potential magnet...
2024-01-16 11:41:19 ET More on ResMed ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards A First Look At ResMed ResMed alerts customers to potential magnetic interference from masks ResMed secures victory in pat...
2024-01-10 22:09:45 ET Summary ResMed, a leader in digital health with over 22.5 million cloud-connected devices sold, excels in treating respiratory disorders like sleep apnea, impacting over 1 billion globally. Recent data from ResMed challenges the misconception that GLP-1 obes...
News, Short Squeeze, Breakout and More Instantly...
2024-06-29 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. He...
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to increase 26.7%...